biote Corp. (BTMD) Stock Score, Valuation & Financial Research
biote Corp. is in the Healthcare sector and Medical - Care Facilities industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. The current Wall Street Score is 45/100.
Quick answer for BTMD
biote Corp. currently has a Wall Street Score of 45/100. The stored market price is $1.39. Its financial score is 23/100. Its valuation score is 100/100. The latest WSS change is +0.2 points. These figures are a research snapshot, not a buy or sell recommendation.
What biote Corp. does
Biote Corp. is dedicated to supporting and developing medical practices that focus on hormone optimization. The company provides a comprehensive system for its Biote-certified healthcare professionals, enabling them to correct imbalances in patients' hormone, vitamin, and mineral levels. This includes authorizing the prescription of bioidentical hormone treatments and suggesting suitable dietary supplements. Furthermore, Biote offers its own line of branded nutritional supplements and supplies sterile kits for inserting hormone pellets for both male and female individuals. Founded in 2011, Biote Corp. is based in Irvine, Texas.
BTMD financial snapshot
- Wall Street Score:
- 45/100
- Current price:
- $1.39
- Market capitalization:
- $61.3M
- Revenue:
- $183.5M
- Net income:
- $5.9M
- Free cash flow:
- $30.2M
- Cash:
- $11.2M
- Total debt:
- $128.6M
- EPS:
- 0.17
- P/E ratio:
- 8.3x
- Financial score:
- 23/100
- Valuation score:
- 100/100
- Revenue score:
- 32/100
What stands out
- Reported year-over-year revenue growth is -0.0%.
- Free cash flow is $30.2M, showing positive cash generation.
- The balance sheet shows $11.2M of cash versus $128.6M of total debt, so leverage deserves attention.
- The latest Wall Street Score change is +0.2 points: BTMD increased 0.2 points because Capital improved by 3 points.
What the numbers mean
Its current valuation score is 100/100, which Wall Street Score classifies as strong within the model's valuation framework.
The financial score is 23/100. This is a starting point for reviewing liquidity, leverage and cash-flow strength rather than a stand-alone recommendation.
A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.
Data freshness: Financial data last refreshed 2026-09-09.
How to research BTMD
Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.
Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks
Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.